Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	33138
Country	Canada

Received	2017-02-06 18:24
Peer-Review Started	2017-02-12 17:47
To Make the First Decision	2017-03-06 18:13
Return for Revision	2017-03-07 15:03
Revised	2017-03-21 05:01
Second Decision	2017-04-10 18:29
Accepted by Journal Editor-in-Chief	2017-04-11 17:36
Accepted by Company Editor-in-Chief	2017-04-19 16:39
Articles in Press	2017-04-19 16:39
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-07-04 01:40
Publish the Manuscript Online	2017-07-12 06:47

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Evolving treatment landscape for early and advanced pancreatic cancer
Manuscript Source	Invited Manuscript
All Author List	Sally C Lau and Winson Y Cheung
Funding Agency and Grant Number
Corresponding Author	Dr. Winson Y Cheung, Department of Oncology, University of Calgary, Tom Baker Cancer Center, 1331 29 ST NW, Calgary, AB T2N 4N2, Canada. wcheung@bccancer.bc.ca
Key Words	Cancer; Neoplasm; Pancreas; Adjuvant treatment; Systemic treatment; Gemcitabine; FOLFIR­INOX; Nab-paclitaxel
Core Tip	Pancreatic ductal adenocarcinoma is an infrequent cancer with high disease mortality. The focus on management of the disease has been mainly palliation for the past decade. Recently, the discovery of active multi-agent chemotherapies such as FOLFIRINOX and gemcitabine plus nab-paclitaxel has changed the management of the disease. In our current review, we will highlight some of the advances, particularly with respect to systemic therapy options, in the management of different stages of pancreatic cancer.
Publish Date	2017-07-12 06:47
Citation	Lau SC, Cheung WY. Evolving treatment landscape for early and advanced pancreatic cancer. World J Gastrointest Oncol 2017; 9(7): 281-292
URL	http://www.wjgnet.com/1948-5204/full/v9/i7/281.htm
DOI	http://dx.doi.org/10.4251/wjgo.v9.i7.281

Full Article (PDF)	WJGO-9-281.pdf
Full Article (Word)	WJGO-9-281.doc
Manuscript File	33138-Review.docx
Answering Reviewers	33138-Answering reviewers.pdf
Audio Core Tip	33138-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	33138-Conflict-of-interest statement.pdf
Copyright License Agreement	33138-Copyright assignment.pdf
Peer-review Report	33138-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	33138-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	33138-Scientific misconduct check.pdf
Scientific Editor Work List	33138-Scientific editor work list.pdf